Silicon-Based Drug Conjugates pH-Dependent Release
Solution Overview
Problem
Current methods for delivering pharmaceuticals and diagnostics face challenges in selective targeting of diseased tissues, leading to non-uniform distribution and systemic toxicity due to unreliable linker chemistries and cleavage mechanisms in antibody-drug conjugates.
Innovation Solution
Development of silicon-based conjugates with a silicon-heteroatom core and targeting moieties that allow for pH-dependent release of payload moieties, ensuring stable delivery and uniform distribution to target cells or tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-drug conjugates are used to deliver drugs to target tissues, then selective delivery is improved, but reliability of drug release and uniform distribution deteriorates due to unreliable linker chemistries
Solution Approach 1:
The patent employs pH-dependent linker chemistries that change their properties based on the local environment. The siloxane and silylether linkers are stable at physiological pH (7.4) but cleave at lower pH values (endosomal/lysosomal environments), enabling controlled drug release while maintaining stable conjugation during circulation. This parameter-based control resolves the contradiction by making drug release reliability dependent on pH conditions rather than statistical distributions.
Solution Approach 2:
The patent introduces silicon-based intermediary linkers (siloxane and silylether moieties) that mediate between the antibody and drug payload. These intermediaries provide a controlled cleavage mechanism through pH-dependent hydrolysis, replacing unreliable statistical distributions with predictable chemistry. The intermediary linker ensures both stable attachment during circulation and reliable release at the target site, improving both selective delivery and uniform distribution.
2Reliability
If high doses of cytotoxic drugs are used to improve therapeutic efficacy, then cancer cell eradication is improved, but systemic toxicity worsens
Solution Approach 1:
The patent creates local quality differences through pH-dependent drug release. The drug conjugate circulates stably in the bloodstream (systemic circulation) and only releases the cytotoxic payload in the acidic environment of endosomes and lysosomes within target cells. This spatial and chemical differentiation allows high doses of cytotoxic drugs to be delivered selectively to cancer cells while minimizing exposure to normal tissues, thereby improving therapeutic efficacy while reducing systemic toxicity.
Solution Approach 2:
The patent converts the potentially harmful acidic environment of endosomes and lysosomes into a beneficial trigger for drug release. The low pH that would normally be considered a challenge for drug stability is instead utilized as the activation mechanism for payload release. This transforms the harmful acidic conditions into a selective release trigger, enabling high-dose cytotoxic therapy with improved safety margins.
3Stability of the object's composition
If drugs are tightly attached to antibodies to prevent premature release, then stability is improved, but drug release and endosomal escape worsen
Solution Approach 1:
The patent introduces dynamic behavior to the drug-antibody conjugate through pH-responsive linker chemistry. The siloxane and silylether linkers maintain stable covalent bonds at physiological pH, ensuring conjugate stability during circulation. Upon encountering the acidic pH of endosomes and lysosomes, the linkers dynamically change their chemical properties and undergo hydrolytic cleavage, enabling reliable drug release. This dynamic response to environmental changes resolves the contradiction between stability and releasability.
Solution Approach 2:
The patent utilizes parameter changes in the linker chemistry based on pH conditions. At pH 7.4 (bloodstream), the siloxane and silylether linkers exhibit high stability with slow hydrolysis rates. At pH 5.0-6.0 (endosomal/lysosomal environment), the linkers undergo accelerated hydrolysis, enabling efficient drug release. This parameter-dependent behavior allows the conjugate to maintain stability during circulation while ensuring reliable release at the target site, resolving the apparent contradiction between these two requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The silicon-based conjugates provide stable delivery and controlled release of therapeutic agents directly to target tissues, minimizing systemic toxicity and improving therapeutic indices by ensuring precise targeting and uniform distribution.
Implementation Method 1
the silicon based conjugate is substantially stable in aqueous solution having a pH of between 7 and 7.5 and hydrolytically cleaves in aqueous solution having a pH less than 7 or greater than 7.5 to release the payload moiety from the conjugate
Data Source
AI summary
Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.